神经激素激活和对转化酶抑制剂的反应在充血性心力衰竭中
1Cardiovascular Division University of Minnesota, Minneapolis 55455.
Circulation
|February 1, 1990
概括
神经激素血管收缩系统在心力衰竭中被激活,但它们的激活不均. 转化酶抑制剂可以改善血液动力学,但对这些系统的长期影响尚不清楚.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经激素血管收缩系统在充血性心力衰竭 (CHF) 中经常被激活.
- 这些系统有助于CHF患者出现异常血管收缩.
研究的目的:
- 为了研究血雷宁活性和北上腺素水平在CHF患者的分布.
- 探索这些标记物与血液动力学,人口统计学和脏因素之间的相关性.
- 评估转化酶抑制剂对CHF血液动力学和神经激素系统的影响.
主要方法:
- 在177名心血管疾病患者中分析了血仁素活性和北上腺素水平.
- 与血液动力学测量,年龄和功能相关性分析.
- 评估转化酶抑制剂对动脉度,预负荷和心脏输出的影响.
主要成果:
- 血雷宁活性和北上腺素水平的广泛分布,表明激活不均.
- 这些标志物与血液动力学参数,年龄和功能之间的弱相关性.
- 转化酶抑制剂显示出有益的血液动力学效应,减少动脉和预负荷,增加心脏输出.
结论:
- 在CHF中,氨酸-血管酶系统和交感神经系统的激活是复杂的和多因素的.
- 转化酶抑制剂在CHF中提供了血液动力学益处.
- 这些抑制剂对神经激素标记物的长期影响及其相互作用需要进一步研究.
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...


